Pentoxifylline ( DrugBank: Pentoxifylline )
12 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
26 | HTLV-1-associated myelopathy | 1 |
56 | Behcet disease | 2 |
84 | Sarcoidosis | 1 |
86 | Pulmonary arterial hypertension | 1 |
93 | Primary biliary cholangitis | 1 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 2 |
113 | Muscular dystrophy | 2 |
220 | Rapidly progressive glomerulonephritis | 1 |
222 | Primary nephrotic syndrome | 1 |
296 | Biliary atresia | 1 |
298 | Hereditary pancreatitis | 1 |
26. HTLV-1-associated myelopathy
Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01472263 (ClinicalTrials.gov) | September 2009 | 11/11/2011 | Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases | Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. | HTLV-1;Tropical Spastic Paraparesis;Immune System Diseases;Physical Disability;Pentoxifylline | Drug: Pentoxifylline;Drug: Placebo | Hospital Universitário Professor Edgard Santos | NULL | Completed | 18 Years | 80 Years | Both | 48 | Phase 3 | Brazil |
56. Behcet disease
Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04186559 (ClinicalTrials.gov) | February 2020 | 2/12/2019 | Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers | Clinical Protocol to Evaluate Use of Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers | Behcet Syndrome;Behcet Disease | Drug: Topical Pentoxifylline Gel (Vehicle +PTX);Drug: Topical Placebo Gel (Vehicle) | Silk Road Therapies, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States |
2 | NCT03888846 (ClinicalTrials.gov) | March 25, 2019 | 21/3/2019 | Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers | Clinical Protocol for Administration of Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers | Behçet Disease Affecting Oral Mucosa | Drug: Pentoxifylline;Drug: Colchicine | Ipekyolu Ilac Ltd. Sti | Istanbul University-Cerrahpasa School of Medicine | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | Turkey |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00001877 (ClinicalTrials.gov) | February 1999 | 3/11/1999 | Treatment of Pulmonary Sarcoidosis With Pentoxifylline | Treatment of Pulmonary Sarcoidosis With Pentoxifylline | Pulmonary Sarcoidosis | Drug: Pentoxifylline | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | N/A | N/A | Both | 100 | Phase 2 | United States |
86. Pulmonary arterial hypertension
Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05611268 (ClinicalTrials.gov) | June 3, 2022 | 24/8/2022 | Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome | Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome: a Randomized Study | Eisenmenger Syndrome | Drug: Pentoxifylline | University of Sao Paulo General Hospital | InCor Heart Institute | Recruiting | 10 Years | 80 Years | All | 48 | N/A | Brazil |
93. Primary biliary cholangitis
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01249092 (ClinicalTrials.gov) | November 2010 | 24/11/2010 | Pentoxifylline for Primary Biliary Cirrhosis | A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis | Primary Biliary Cirrhosis | Drug: Pentoxifylline | The Cleveland Clinic | NULL | Completed | 18 Years | 76 Years | All | 20 | Phase 2 | United States |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02953275 (ClinicalTrials.gov) | April 13, 2017 | 31/10/2016 | Synergistic Effect of Vedolizumab and Pentoxifylline | Synergistic Effect of Vedolizumab and Pentoxifylline in the Management of Patients With Inflammatory Bowel Disease | Crohn Disease | Drug: vedolizumab;Drug: Pentoxifylline;Drug: placebo | University of Miami | Takeda | Completed | 18 Years | 80 Years | All | 37 | Early Phase 1 | United States |
97. Ulcerative colitis
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05575505 (ClinicalTrials.gov) | February 2, 2023 | 8/10/2022 | Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis. | Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis. | Inflammatory Bowel Diseases | Drug: Pentoxifylline 400 MG | Tanta University | NULL | Recruiting | 18 Years | 75 Years | All | 44 | Phase 2 | Egypt |
2 | NCT05558761 (ClinicalTrials.gov) | October 10, 2022 | 25/9/2022 | Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis | Clinical Study to Evaluate the Possible Efficacy of Pentoxifylline in Patients With Ulcerative Colitis Treated With Mesalamine | Inflammatory Bowel Diseases | Drug: Pentoxifylline 400 MG | Tanta University | NULL | Recruiting | 18 Years | 75 Years | All | 50 | Phase 2 | Egypt |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00243789 (ClinicalTrials.gov) | September 2005 | 21/10/2005 | Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy | A Double-Blinded Randomized Placebo Controlled Study of Daily Pentoxifylline as a Rescue Treatment in DMD | Muscular Dystrophy, Duchenne | Drug: Pentoxifylline | Cooperative International Neuromuscular Research Group | NULL | Completed | 7 Years | N/A | Male | 64 | Phase 1/Phase 2 | United States;Argentina;Australia;Canada;Israel;Italy |
2 | NCT00102453 (ClinicalTrials.gov) | March 2002 | 29/1/2005 | Pentoxifylline in Duchenne Muscular Dystrophy | An Open-Label Pilot Study of Pentoxifylline in Steroid-naive Duchenne Muscular Dystrophy | Muscular Dystrophy, Duchenne | Drug: Pentoxifylline | Cooperative International Neuromuscular Research Group | NULL | Completed | 4 Years | 7 Years | Male | 17 | Phase 1/Phase 2 | United States |
220. Rapidly progressive glomerulonephritis
Clinical trials : 2 / Drugs : 4 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathway : 1
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00354198 (ClinicalTrials.gov) | August 2006 | 18/7/2006 | Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis | Clinical Efficacy of Combined Pentoxifylline and Conventional Immunosuppressive Regimens on Patients With Rapidly Progressive Glomerulonephritis | Glomerulonephritis | Drug: pentoxifylline;Drug: corticosteroids | National Taiwan University Hospital | National Science Council, Taiwan | Terminated | 20 Years | 80 Years | Both | 7 | Phase 3 | Taiwan |
222. Primary nephrotic syndrome
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00354731 (ClinicalTrials.gov) | August 2006 | 18/7/2006 | Efficacy of Pentoxifylline on Primary Nephrotic Syndrome | Clinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic Syndrome | Nephrotic Syndrome | Drug: pentoxifylline;Drug: Corticosteroid | National Taiwan University Hospital | National Science Council, Taiwan | Completed | 20 Years | 80 Years | Both | 62 | Phase 3 | Taiwan |
296. Biliary atresia
Clinical trials : 71 / Drugs : 70 - (DrugBank : 39) / Drug target genes : 35 - Drug target pathways : 60
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01774487 (ClinicalTrials.gov) | February 4, 2013 | 22/1/2013 | Pentoxifylline Therapy in Biliary Atresia | A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia | Biliary Atresia | Drug: Pentoxifylline | Baylor College of Medicine | NULL | Terminated | N/A | 180 Days | All | 17 | Phase 2 | United States |
298. Hereditary pancreatitis
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02487225 (ClinicalTrials.gov) | May 2015 | 29/6/2015 | Pentoxifylline Treatment in Acute Pancreatitis (AP) | Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial | Acute Pancreatitis (AP);Gallstone Pancreatitis;Alcoholic Pancreatitis;Trauma Acute Pancreatitis;Hypertriglyceridemia Acute Pancreatitis;Idiopathic (Unknown) Acute Pancreatitis;Medication Induced Acute Pancreatitis;Cancer Acute Pancreatitis;Miscellaneous (i.e. Acute on Chronic Pancreatitis) | Drug: Pentoxifylline;Drug: Placebo | Mayo Clinic | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 18 Years | 100 Years | All | 83 | Phase 3 | United States |